Clinical trials: Tace
Hepatocellular Carcinoma (HCC)
A Pilot Study of Trans Arterial Chemoembolization (TACE), Followed by Stereotactic Radiation Therapy (SBRT) for Patients With Hepatocellular Carcinoma
This investigational study will evaluate if using a combination of TACE along with high dose SBRT would show improvement in local control in patients with Hepatocellular Carcinoma.
- Trial name
- RAD 0902 (NCT01247298)
- Testing
- Stereotactic Body Radiation Therapy (SBRT)
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Alabama at Birmingham
Precision Cells, Chemotherapy
Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer
Objectives: To evaluate the safety and effectiveness of cell therapy using precision cells to treat Advanced Lung Cancer. Eligibility: Individuals greater than or equal to 18 years of age and less than or equal to 65 years of age…
- Conditions
- Precision Cells, Chemotherapy, Advanced Lung Cancer
- Trial name
- NCT02862587
- Testing
- Chemotherapy, precision cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai International Medical Center
Hepatocellular Carcinoma
Combine TACE and RFA Versus TACE Alone for HCC With PVTT
The purpose of this study is to determine whether combined radiofrequency ablation and transcatheter chemoembolization (TACE) result in better survival outcomes than TACE alone in patients with HCC and portal vein tumor thrombus.
- Trial name
- CORTT (NCT02301091)
- Testing
- TACE, RFA, pirarubicin,mitomycin and lobaplatin
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Ming Zhao
HCC, Transarterial Chemoembolization
A New Conception About Individualized Treatment Allocation for HCC
The current guidelines on hepatocellular carcinoma (HCC) aimed to build effective prognostic stratification strategies to guide therapeutic allocation; however, the current guidelines did not consider the simultaneous comparison…
- Conditions
- HCC, Transarterial Chemoembolization, Resection
- Trial name
- PTA4HCC (NCT06008548)
- Testing
- TACE
- Volunteers
- 4,991 people
- Sponsor
- Tang-Du Hospital
Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Carcinoma
Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma
Safety and Efficacy Evaluation of Tremelimumab Plus Durvalumab(MEDI4736) in Combination with Concurrent Transarterial Chemoembolization in Unresectable Hepatocellular carcinoma
- Trial name
- NCT06911255
- Testing
- Tremelimumab Plus Durvalumab (MEDI4736), Transarterial chemoembolization (TACE)
- Where
- South Korea
- Volunteers
- 24 people
- Sponsor
- Yoon Jun Kim
Carcinoma, Hepatocellular
TATE Versus TACE in Intermediate Stage HCC
An open label randomized study to compare TATE versus TACE in patients with intermediate stage Hepatocellular carcinoma who are not suitable for surgical resection or radiofrequency ablation.
- Trial name
- TATE (NCT03145558)
- Testing
- Tirapazamine, Doxorubicin
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Teclison Ltd.
Colorectal Liver Metastases (CRCLM)
To Evaluate the Performance of HepaSphere Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy on Unresectable Colorectal Liver Metastases
Both drug-eluting bead transarterial chemoembolization (DEB-TACE) and hepatic arterial infusion chemotherapy (HAIC) are recommended for unresectable colorectal liver metastases (CRLM) treatment.
- Trial name
- NCT05889325
- Testing
- DEB-TACE plus HAIC
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University Cancer Hospital & Institute
Hepatocellular Carcinoma
Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria
The purpose of this study is to evaluate the efficacy and safety of lenvatinib combined with PD-1 antibody compared with transarterial chemoembolization (TACE) for patients with intermediate-stage hepatocellular carcinoma (HCC)…
- Trial name
- NCT03791918
- Testing
- Lenvatinib, PD-1 antibody, TACE
- Where
- 3 sites in China
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
Radiotherapy Versus no Intervention in Adult Patients With Hepatocellular Carcinoma Not Eligible for Transarterial Chemoembolization or Ablation Prior to Liver Transplant (RADBRI)
Liver transplantation (LT) represents the best treatment for patients with selected, early stage hepatocellular carcinoma (HCC).
- Trial name
- RADBRI (NCT03172559)
- Testing
- Stereotactic body radiotherapy
- Sponsor
- University Health Network, Toronto
Unresectable Liver Cancer
Study on the Efficacy and Safety of Transarterial Chemoembolization Combined With Targeted Immunotherapy in Patients With Unresectable Hepatocellular Carcinoma
This study is a single-center, single-arm, prospective study. It enrolls patients with unresectable hepatocellular carcinoma (HCC).
- Trial name
- NCT06715072
- Volunteers
- 70 people
- Sponsor
- Yao Xie
Precision Cell Immunotherapy, Transcatheter Arterial Chemoembolization
Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer
To evaluate the safety and effectiveness of cell therapy using precision cells Combined With TACE in Advanced Liver Cancer. Eligibility: Individuals greater than or equal to 18 years of age and less than or equal to 65 years of…
- Conditions
- Precision Cell Immunotherapy, Transcatheter Arterial Chemoembolization, Advanced Liver Cancer
- Trial name
- NCT02873442
- Testing
- TACE, Precision Cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Ningbo Cancer Hospital
Hepatocellular Carcinoma (HCC)
The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study
This is a multicenter, retrospective study planned to enroll patients with unresectable hepatocellular carcinoma (uHCC) who received first-line donafenib combined with an anti-PD-1/L1 monoclonal antibody and either TACE or HAIC…
- Trial name
- NCT07724951
- Testing
- Donafeinib, Transcatheter arterial chemoembolization, PD-1 / PD-L1 monoclonal antibody
- Where
- 8 sites in China
- Volunteers
- 400 people
- Sponsor
- Shanghai Zhongshan Hospital
Carcinoma, Hepatocellular
A Prospective, Randomized, Multicenter Study of Comparison of TACE Combination With and Without EBRT for Hepatocellular Carcinoma With Portal Vein Tumor Thrombi
The 1-year and 2-year overall survival rate (OS), local control rate (FFLP), disease-free progression time (PFS), and side effects were compared in patients with hepatocellular carcinoma limited to intrahepatic unresectable…
- Trial name
- NCT03939845
- Testing
- RT, TACE
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Shanghai Zhongshan Hospital
Unresectable Hepatocellular Carcinoma
SIRT Versus cTACE for Unresectable HCC (CHANCE2506)
To evaluate the efficacy and safety of yttrium-90 carbon microspheres versus cTACE in patients with unresectable hepatocellular carcinoma
- Trial name
- NCT06909708
- Testing
- SIRT, cTACE
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Zhongda Hospital
PHENYTOIN/SORAFENIB [VA Drug Interaction], Liver Neoplasms
Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma
Transarterial chemoembolization (TACE) is widely used for unresectable hepatocellular carcinoma (HCC). However, the hypoxia caused by TACE in surviving tumor cell leads to release of angiogenic and growth factors contributing to…
- Conditions
- PHENYTOIN/SORAFENIB [VA Drug Interaction], Liver Neoplasms, Carcinoma, Hepatocellular, Digestive System Neoplasms
- Trial name
- NCT01556815
- Testing
- Transarterial Chemoembolization (TACE), Sorafenib in combination with TACE
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shandong Cancer Hospital and Institute
Hepatocellular Carcinoma
Pharmacogenetic Study in Hepatocellular Carcinoma Patients.
evaluate the prognostic value of genetic polymorphisms in HCC Egyptian patients undergoing TACE using lipiodol and doxorubicin.
- Trial name
- NCT05291338
- Testing
- Doxorubicin, Lipiodol
- Where
- Egypt
- Volunteers
- 107 people
- Sponsor
- Rehab Werida
Hepatocellular Carcinoma
AI-Based Multimodal Integration for Tumor Microenvironment Analysis and Response Prediction in HCC Treated With TACE Plus Immunotherapy and Targeted Therapy (CHANCE2601)
This study aims to prospectively validate a retrospective cohort-derived AI-based multimodal model and explore tumor heterogeneity and the immune microenvironment to guide TACE combined with immunotherapy and targeted therapy in…
- Trial name
- NCT07584317
- Testing
- Artificial Intelligence
- Volunteers
- 1,170 people
- Sponsor
- Gao-jun Teng
HepatoCellular Carcinoma
The Impact on Therapeutic Effect and Tolerance of Treatment for Patients With Hepatocellular Carcinoma in Transcatheter Arterial Chemoembolization (TACE) of Dexamethasone Application: A Random, Double-blind, Controlled, Clinical Trial.
The current random, double-blind, controlled, clinical trial was designed to evaluate the impact on therapeutic effect and tolerance of treatment for patients with hepatocelluclar carcinoma in transcatheter arterial…
- Trial name
- NCT02987907
- Testing
- Dexamethasone, Normal Saline
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
Sorafenib With TACE to Treat Hepatocellular Carcinoma
The purpose of this study is to determine the feasibility to combine sorafenib with transarterial chemoembolisation in patients suffering from hepatocellular carcinoma.The hypothesis is that sorafenib may prevent the development…
- Trial name
- S-TACE (NCT00478374)
- Testing
- Sorafenib, Transarterial chemoembolisation with doxorubicin
- Where
- Switzerland
- Volunteers
- 21 people
- Sponsor
- University of Bern
Hepatocellular Carcinoma
Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma
Trans-arterial chemoembolization (TACE) is the most commonly used therapy for patients with unresectable hepatocellular carcinoma (HCC).
- Trial name
- TAQE (NCT05842174)
- Testing
- Hydroxychloroquine, Lipiodol
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- VA Office of Research and Development